Is AbbVie Stock A Buy After Earnings? Consider Revenue Outlook And Valuations


  • AbbVie’s Q4 2022 earnings beat market expectations, but ABBV’s full-year 2022 bottom line came in below its prior management guidance.
  • ABBV’s revenue growth is expected to slow in the next couple of years, with market share loss for Imbruvica being a key factor.
  • I rate AbbVie’s shares as a Hold, after taking into account both its topline growth prospects and forward P/E valuation multiple.

AbbVie headquarters building facade of an American publicly traded biopharmaceutical company

Michael Vi

Elevator Pitch

AbbVie Inc. (NYSE:ABBV) describes itself as a “biopharmaceutical company” boasting “leadership positions across immunology, hematologic oncology, neuroscience, aesthetics, and eye care” in the company’s 10-K filings. ABBV recently announced the company’s fourth quarter and

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount, e.g., net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions and wide moat compounders). Sign up here to get started today!

Leave a Reply

Your email address will not be published. Required fields are marked *